← Back to Financial

Labcorp and Chemed Shares Hit Records on Earnings Beats and Upgrades

FinancialAI-Generated & Algorithmically Scored·

AI-generated from multiple sources. Verify before acting on this reporting.

NEW YORK — Shares of diagnostic services provider Labcorp Holdings Inc. and healthcare holding company Chemed Corp. surged to record highs Monday following better-than-expected third-quarter earnings and a wave of analyst upgrades from major investment banks.

Labcorp stock climbed more than 8 percent in early trading, while Chemed shares rose nearly 7 percent, marking new all-time highs for both companies on the New York Stock Exchange. The rally was driven by robust financial results released late Sunday that exceeded Wall Street projections and prompted immediate reassessments of the firms' growth trajectories.

Labcorp reported third-quarter revenue and earnings per share that surpassed analyst estimates, citing strong demand across its clinical chemistry and molecular testing segments. In a move that further buoyed investor sentiment, the company raised its full-year guidance, signaling confidence in sustained demand for its diagnostic services despite broader economic uncertainties. The upgrade was led by analysts at Leerink Partners and Jefferies, who cited the company's operational efficiency and expanding market share as key drivers for future performance.

Chemed Corp., known for its VITAS Healthcare hospice division, also posted a significant earnings beat. The company attributed the strong quarter to accelerated growth within its VITAS business, which saw increased patient admissions and improved operating margins. Barclays analysts upgraded their price target on Chemed following the release, highlighting the resilience of the home health care sector and the company's successful cost-management strategies.

The simultaneous surge for both entities underscores a broader trend in the U.S. healthcare sector, where companies demonstrating clear paths to profitability and growth are being rewarded by equity markets. The upgrades from Leerink, Jefferies, and Barclays reflect a shifting sentiment toward diagnostic and home care providers as essential components of the evolving healthcare landscape.

While the immediate market reaction has been overwhelmingly positive, questions remain regarding the sustainability of these growth rates in the coming quarters. Investors are closely watching for potential headwinds, including regulatory changes affecting reimbursement rates and ongoing labor shortages that could impact staffing levels at diagnostic labs and hospice facilities. Additionally, the extent to which the raised guidance for Labcorp can be maintained through a potentially volatile fourth quarter remains a key variable for analysts.

Market participants will continue to monitor upcoming commentary from company executives during earnings calls to gauge long-term strategic shifts. As trading continues, both stocks have held their gains, suggesting that the market views these results as a fundamental re-rating rather than a temporary spike. The performance of Labcorp and Chemed sets a high bar for other healthcare peers expected to report earnings in the coming weeks.

Discussion

0 / 2000